These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30801958)

  • 1. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells.
    Kilani B; Gourdou-Latyszenok V; Guy A; Bats ML; Peghaire C; Parrens M; Renault MA; Duplàa C; Villeval JL; Rautou PE; Couffinhal T; James C
    J Thromb Haemost; 2019 May; 17(5):827-840. PubMed ID: 30801958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors.
    He Q; Li X; Singh K; Luo Z; Meija-Cordova M; Jamalpour M; Lindahl B; Kriz V; Vuolteenaho R; Ulvmar M; Welsh M
    Sci Rep; 2019 May; 9(1):7548. PubMed ID: 31101877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inducible von Willebrand Factor Cre recombinase mouse strain to study microvascular endothelial cell-specific biological processes in vivo.
    Yadav D; Conner JA; Wang Y; Saunders TL; Ubogu EE
    Vascul Pharmacol; 2024 Jun; 155():107369. PubMed ID: 38554988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen-inducible NaV1.8-CreERT2 recombinase activity in nociceptive neurons of dorsal root ganglia.
    Zhao J; Nassar MA; Gavazzi I; Wood JN
    Genesis; 2006 Aug; 44(8):364-71. PubMed ID: 16850455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient, inducible Cre-recombinase activation in vascular endothelium.
    Claxton S; Kostourou V; Jadeja S; Chambon P; Hodivala-Dilke K; Fruttiger M
    Genesis; 2008 Feb; 46(2):74-80. PubMed ID: 18257043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of LysM-cre and Cdh5-cre Driver Mice in Retinal and Brain Research: An Imaging Study Using tdTomato Reporter Mouse.
    Fouda AY; Xu Z; Narayanan SP; Caldwell RW; Caldwell RB
    Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):51. PubMed ID: 32232350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium.
    Monvoisin A; Alva JA; Hofmann JJ; Zovein AC; Lane TF; Iruela-Arispe ML
    Dev Dyn; 2006 Dec; 235(12):3413-22. PubMed ID: 17072878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating endogenous Myh11-driven Cre mice for sex-independent gene deletion in smooth muscle cells.
    Zhao Y; Zhao G; Chang Z; Zhu T; Zhao Y; Lu H; Xue C; Saunders TL; Guo Y; Chang L; Chen YE; Zhang J
    JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37289544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial cell-specific expression of Cre recombinase in transgenic mice.
    Li WL; Cheng X; Tan XH; Zhang JS; Sun YS; Chen L; Yang X
    Yi Chuan Xue Bao; 2005 Sep; 32(9):909-15. PubMed ID: 16201233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pou4f2 knock-in Cre mouse: A multifaceted genetic tool for vision researchers.
    Simmons AB; Bloomsburg SJ; Billingslea SA; Merrill MM; Li S; Thomas MW; Fuerst PG
    Mol Vis; 2016; 22():705-17. PubMed ID: 27390513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.
    Hameyer D; Loonstra A; Eshkind L; Schmitt S; Antunes C; Groen A; Bindels E; Jonkers J; Krimpenfort P; Meuwissen R; Rijswijk L; Bex A; Berns A; Bockamp E
    Physiol Genomics; 2007 Sep; 31(1):32-41. PubMed ID: 17456738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gcg
    Shiota C; Prasadan K; Guo P; Fusco J; Xiao X; Gittes GK
    Diabetologia; 2017 Dec; 60(12):2399-2408. PubMed ID: 28884202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pdgf-c
    Wu X; Liu W; Ding H
    Genesis; 2018 Feb; 56(2):. PubMed ID: 29345101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2.
    Hirrlinger PG; Scheller A; Braun C; Hirrlinger J; Kirchhoff F
    Glia; 2006 Jul; 54(1):11-20. PubMed ID: 16575885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse.
    Lau J; Minett MS; Zhao J; Dennehy U; Wang F; Wood JN; Bogdanov YD
    Mol Pain; 2011 Dec; 7():100. PubMed ID: 22188729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mds1
    Zhang Y; McGrath KE; Ayoub E; Kingsley PD; Yu H; Fegan K; McGlynn KA; Rudzinskas S; Palis J; Perkins AS
    Cell Rep; 2021 Aug; 36(7):109562. PubMed ID: 34407416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sox17CreERT2 knock-in mouse line displays spatiotemporal activation of Cre recombinase in distinct Sox17 lineage progenitors.
    Engert S; Burtscher I; Kalali B; Gerhard M; Lickert H
    Genesis; 2013 Nov; 51(11):793-802. PubMed ID: 24038996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site- and time-specific gene targeting in the mouse.
    Metzger D; Chambon P
    Methods; 2001 May; 24(1):71-80. PubMed ID: 11327805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cre-mediated recombination efficiency and transgene expression patterns of three retinal bipolar cell-expressing Cre transgenic mouse lines.
    Lu Q; Ivanova E; Ganjawala TH; Pan ZH
    Mol Vis; 2013; 19():1310-20. PubMed ID: 23805038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mouse model with tamoxifen-inducible thyrocyte-specific cre recombinase activity.
    Undeutsch H; Löf C; Offermanns S; Kero J
    Genesis; 2014 Apr; 52(4):333-40. PubMed ID: 24395757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.